Philip Morris International Inc. (PM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong smoke-free product growth, particularly in the U.S. with ZYN, and a solid adjusted operating income margin. Despite some uncertainties in guidance and competitive pressures, the overall sentiment is positive due to the company's strategic focus on growth markets and innovation. The Q&A section highlighted growth opportunities in the U.S. and Japan, and the company's resilience in managing excise impacts and competition. While there are some concerns, the strategic direction and financial health suggest a positive outlook for the stock price.
Key Financial Performance
Smoke-free products volumes Grew by 12.8% year-over-year. This growth was driven by the increasing profitability of the portfolio, reflected in organic smoke-free gross profit growth of 18.7%. IQOS shipments and adjusted IMS grew around 11%, with strong growth in Italy and Taiwan.
Adjusted diluted EPS Increased by 15% in dollar terms year-over-year, marking the strongest growth since 2011 (excluding the pandemic recovery year of 2021). This reflects currency-neutral growth of 14%, driven by strong business performance, favorable tax rates, and lower net financing costs.
Organic net revenue growth Achieved 6.5% growth year-over-year, or 7.9% excluding the technical Indonesia impact. This was driven by positive shipment volumes, strong smoke-free category mix, and pricing.
Organic operating income growth Increased by 10.6% year-over-year, reflecting 140 basis points of organic margin expansion. In dollar terms, adjusted operating income grew by 11.8% to $16.4 billion.
Operating cash flow Remained robust at $12.2 billion, matching the record delivery of 2024.
Smoke-free shipments Grew by 12.8% to 179 billion units, offsetting a 1.5% decline in cigarette shipments. This includes 11% growth in IQOS HTU shipments, 102% growth in VEEV, and 18.5% growth in oral smoke-free products.
Gross margin Expanded organically by 220 basis points to over 67%. Smoke-free gross profit advanced by 18.7%, with adjusted gross margin increasing by 270 basis points to 69.5%.
Combustible pricing Achieved 7.6% pricing growth, which offset volume declines and unfavorable mix, leading to gross margin expansion of 160 basis points to 65.5%.
ZYN shipments in the U.S. Grew by 37% year-over-year to 794 million cans, despite supply constraints and competitive portfolio gaps.
Adjusted operating income margin Reached 40.4%, reflecting 140 basis points of organic expansion and 160 basis points in dollar terms.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Smoke-free products: Volumes grew by 12.8%, with organic gross profit growth of 18.7%. IQOS shipments and adjusted IMS grew around 11%. ZYN and VEEV more than doubled shipment volumes in international markets.
Nicotine pouches (ZYN): Gained significant international share, with shipments growing by 37% in the U.S. despite supply constraints. Expanded portfolio and market reach.
E-vapor (VEEV): Fastest-growing brand in international closed pods, holding #1 position in 8 markets with substantial gross profit increase.
Geographic expansion: Smoke-free products now available in 106 markets, with 52 deploying a multi-category strategy. Europe region surpassed 50% smoke-free net revenue.
U.S. market: ZYN grew shipments by 37%, capturing 61.5% can volume share and over 67% value share in the nicotine pouch category.
Japan: Heat-not-burn category crossed 50% of total industry volumes, driven by IQOS.
Cost savings: Achieved $1.5 billion in gross cost savings since 2024, on track for $2 billion by 2026.
Cash generation: Operating cash flow of $12.2 billion in 2025, matching 2024 record levels.
Adjusted operating margin: Returned to above 40% in 2025, supported by disciplined cost management and investment in smoke-free products.
Transformation to smoke-free: 41.5% of total net revenues in 2025 were from smoke-free products, with 27 markets exceeding 50% net revenue milestone.
Innovation and digitalization: Focus on new initiatives and innovations over the next 3 years, supported by increasing digitalization and a new organizational model.
U.S. regulatory strategy: Preparing for FDA submissions for ZYN Ultra and IQOS ILUMA to address broader consumer preferences and expand market presence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Issues in Turkey: Supply chain disruptions in Turkey impacted the performance of combustibles, posing challenges to maintaining robust top and bottom-line performance.
Regulatory Challenges in Japan: Upcoming excise tax increases on heat-not-burn products in Japan are expected to negatively impact category growth and volumes in 2026, creating headwinds for the business.
Competitive Pressures in Smoke-Free Products: Increased competitive intensity in the heat-not-burn category, particularly in Japan, has created challenges in maintaining market share and growth momentum.
Economic Uncertainties in Key Markets: Inflationary pressures in markets like Japan have impacted consumer purchasing power, potentially affecting sales and growth in the heat-not-burn category.
U.S. Regulatory Environment for Nicotine Pouches: Navigating the dynamic and uncertain regulatory environment in the U.S. for nicotine pouches, including pending FDA submissions, poses risks to product launches and market expansion.
Inventory Management Challenges in the U.S.: Surplus inventory in the U.S. supply chain for ZYN nicotine pouches may lead to shipment volatility and impact growth projections in 2026.
Excise Tax Increases in India and Mexico: Recent excise tax increases in India and Mexico are expected to weaken industry volumes, impacting the performance of combustibles in these markets.
Currency Volatility: Nonrecurring transactional losses related to currency fluctuations, such as the Russian ruble and Swiss franc, have negatively impacted financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Renewed 3-Year Growth Targets (2026-2028): The company targets a compound annual growth rate (CAGR) of 6%-8% in organic net revenues, 8%-10% in organic operating income, and 9%-11% in adjusted diluted EPS at constant currency. Smoke-free product shipment and adjusted IMS volume growth are expected to be in the high single digits to low teens.
2026 Financial Projections: The company forecasts organic net revenue growth of 5%-7%, organic operating income growth of 7%-9%, and currency-neutral adjusted diluted EPS growth of 7.5%-9.5%. Including a $0.28 currency benefit, this translates to 11.3%-13.3% growth in adjusted diluted EPS to a range of $8.39-$8.54.
Smoke-Free Product Growth: High single-digit growth is projected for smoke-free product shipments and adjusted IMS volumes in 2026, despite headwinds from Japan excise taxes and U.S. ZYN inventory comparisons. The company targets smoke-free product shipment and adjusted IMS volume growth of high single digits to low teens for 2026-2028.
U.S. Market Expansion: The company plans to launch ZYN Ultra, pending FDA approval, and expand its U.S. presence with IQOS ILUMA. ZYN is expected to deliver best-in-class gross margins and significant growth potential over the coming years.
Capital Expenditures and Cash Flow: The company anticipates capital expenditures of $1.3 billion to $1.5 billion per annum on average for 2026-2028, with the majority focused on smoke-free products. Aggregate operating cash flow is targeted at around $45 billion over the next three years.
Dividend and Leverage Targets: The company aims to maintain a dividend payout ratio of around 75% of adjusted diluted EPS and pursue dividend growth closer to earnings growth. It targets a leverage ratio of close to 2x by the end of 2026.
Market Trends and Regional Performance: The heat-not-burn category in Japan surpassed 50% of total industry volumes in December 2025. The company expects continued growth in smoke-free products across Europe, Asia, and the U.S., with a focus on multi-category strategies and innovation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend payout ratio: The dividend payout ratio is now close to the company's objective of around 75% of adjusted diluted EPS.
Dividend growth: The company has the capacity to pursue dividend growth closer to the level of earnings growth, as demonstrated by the 8.9% increase announced in September last year.
Share repurchase program: No specific share repurchase program was mentioned in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you expand on the reacceleration in smoke-free volume growth compared to the 2026 growth guidance? How are other currently closed markets and the opportunity to expand platforms into existing IQOS markets considered?
A:The reacceleration in smoke-free volume growth beyond 2026 is expected due to tax changes in Japan, which will create symmetry between heated tobacco products and cigarettes. The U.S. market is seen as a significant growth opportunity despite its current small weight in total smoke-free volumes. Other factors include excise increases in markets like India and Mexico, which are not expected to recur after 2026. Innovations will also play a role, but specific details were not disclosed for competitive reasons.
Q:How are you thinking about IQOS HTU shipments and IMS in terms of the 2026 guidance for smoke-free volumes?
A:IQOS is performing well despite increased competition in Japan. The company avoids providing specific volume guidance for individual geographies but incorporates all factors, including competition and excise impacts, into its overall smoke-free product volume guidance. Growth is expected in markets like Europe, Indonesia, Philippines, and Mexico, with strong performance in Taiwan.
Q:Does the 2026 guidance include anything for ILUMA in the U.S., and is there something included for the 2027-2028 timeframe?
A:The 2026 guidance does not heavily depend on IQOS ILUMA in the U.S., but some assumptions for its entry into the U.S. market are included for the 2027-2028 timeframe. The guidance includes investments and expected volumes for IQOS.
Q:Can you talk more about the elasticities you're expecting with volumes in Japan due to excise tax increases? Will the incremental pricing drive margin expansion and income growth in the region?
A:The excise tax increases in Japan will impact consumer prices starting April 1, 2026, with another increase in October. While the immediate impact on margins may vary depending on pricing strategies, the company aims for long-term margin expansion. Specific pricing strategies were not disclosed.
Q:What are the key growth drivers that will allow you to deliver on your top and bottom line guidance for 2026?
A:Key growth drivers include a dynamic smoke-free portfolio, resilience in the combustible business despite challenges in markets like India and Mexico, and continued investments in ZYN and IQOS. The company expects low single-digit revenue growth and low to mid-single-digit gross profit growth in combustibles, with strong performance in smoke-free products.
Q:What technical or functional attributes could further improve consumer conversion for IQOS in emerging markets?
A:The company did not disclose specific innovations or attributes for competitive reasons but acknowledged the importance of continuous innovation to improve consumer conversion.
Q:Why has there been a notable absence of ZYN promotions in the U.S. over the last two months?
A:The absence of ZYN promotions in the U.S. was due to deliberate decisions not to repeat certain schemes from Q3 and Q4. The company emphasized the importance of a balanced marketing mix, including brand-building, portfolio adjustments, and pricing strategies, to drive long-term success.
Q:What are your thoughts on the potential excise tax increase on nicotine pouches in New York and its impact on the promotional environment or competitive landscape?
A:The company views the proposed excise tax increase on nicotine pouches in New York as counterproductive to public health objectives. It believes such measures undermine the health benefits of these products compared to cigarettes. The impact on the promotional environment or competitive landscape was not detailed.
Q:Should we expect a similar level of cost savings for the medium-term guidance to the end of 2028, and what role might AI play in accelerating cost savings?
A:While specific cost savings for the medium-term were not quantified, the company aims to continue driving efficiency, including leveraging AI for cost performance. Approximately 60% of current cost savings come from COGS, with the rest from back-office and G&A efficiencies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on innovations for competitive reasons, did not disclose precise pricing strategies for Japan, and refrained from predicting the timing of FDA approvals for ZYN Ultra. Additionally, they did not provide detailed hedge rates for key currencies or elaborate on the potential impact of the proposed excise tax increase on nicotine pouches in New York.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA action
Formula
Italy Romania
JPY
Marlboro share
Poland Italy
Taiwan
VEEV volume
ZYN brand
ZYN pouch
ZYN share
adult smoker
alternative
average IQOS
brand player
burn category
can shipment
cash generation
category industry
category market
category trend
currency expectation
example
heat burn
increase category
industry volume
intensity
market sale
market shipment
milestone
nicotine consumer
nicotine industry
normalization ZYN
penetration
player pod
premium
presence market
product volume
profitability
smoke market
start
volume decline
PM Transcript
Philip Morris International Inc. (PM) Presents at 23rd annual dbAccess Global Consumer Conference Transcript
Neutral6-2
Philip Morris International Inc. (PM) Presents at Consumer Analyst Group of New York Conference 2026 Transcript
Neutral2-18
Philip Morris International Inc. (PM) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call reveals strong smoke-free product growth, particularly in the U.S. with ZYN, and a solid adjusted operating income margin. Despite some uncertainties in guidance and competitive pressures, the overall sentiment is positive due to the company's strategic focus on growth markets and innovation. The Q&A section highlighted growth opportunities in the U.S. and Japan, and the company's resilience in managing excise impacts and competition. While there are some concerns, the strategic direction and financial health suggest a positive outlook for the stock price.
Philip Morris International Inc. (PM) Presents at Morgan Stanley Global Consumer & Retail Conference 2025 Transcript
Neutral12-2
PM Slides
PM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
